Validity verdict (step 6)
approved, checked. Reconstruction: premise is that in a prospective design exposure is recorded before outcome, and that early-event exclusion + lagged analysis drop the sub-population whose baseline exposure was perturbed by incipient (undiagnosed) disease; conclusion is that reverse causation from subclinical disease is thereby removed, yielding “reasonably unbiased” estimates. Traced step: if the individuals whose exposure was altered by preclinical disease are exactly those who convert to the outcome within the exclusion/lag window, then removing early events removes precisely the members through whom this reverse-causation pathway operates — the mechanism-and-remedy match, so the step goes through for that pathway. The obvious undercutting probe (the preclinical period outlasts the chosen window, leaving residual reverse causation) is not a defeater to the step conditional on its premises: the argument builds in the assumption that the latency window is chosen long enough, which is a reasonable charitable premise, not completion-by-force. The claim is correctly scoped — “reverse causation,” not confounding or measurement error — and is hedged (“reasonably unbiased,” “handled … rather than intractable”), so no weaker form is needed. Author-blind: rests on the design logic, not on the source.
Reasoning
In a prospective design the exposure is recorded before the outcome occurs, so gross reverse causation (the disease causing the reported exposure) is structurally limited relative to case-control or cross-sectional designs. The residual concern is subclinical/preclinical disease that changes the exposure before diagnosis — e.g. undiagnosed illness causing weight loss and appetite/diet changes years before death, which spuriously links low BMI or altered intake to mortality. This specific mechanism is removed by (i) excluding events (e.g. deaths) in the first several years of follow-up, so that people whose baseline exposure was already perturbed by incipient disease do not contribute, and (ii) lagged analyses that relate exposure to outcomes only after a latency window. Satija argues these yield “reasonably unbiased estimates.” The inference is valid for the preclinical-disease pathway it targets: exclusions/lags remove the sub-population in which reverse causation operates. It does not address confounding or measurement error (handled separately), and it assumes the latency window is chosen long enough to outlast the preclinical period — too short a window leaves residual reverse causation.